


Additional file 6: Figure S2 Waterfall plot of target lesions shrinkage



Shrinkage of target lesion in evaluable patients receiving osimertinib based upon the presence of the T790M mutation detected on ctDNA by tag-based NGS is shown. Cut-offs for progressive disease (+20%) and partial response (-30%) are indicated as per RECIST 1.1. The original sensitizing mutation of each patient is shown (black and grey histograms indicate T790M-positive and T790M-negative patients by Real Time PCR, respectively) . del, deletions; ins, insertions.